Semaglutide for T2s

The European Medicines Agency’s human medicines committee (CHMP) has recommended granting a marketing authorization in the EU for Rybelsus (semaglutide) for the treatment of adults with insufficiently controlled Type 2 diabetes to improve glycaemic control as an adjunct to diet and exercise. It is the first glucagon-like peptide (GLP-1) receptor agonist treatment (a class of non-insulin medicines for people with type 2 diabetes) developed for oral use, providing patients with another option to treat the disease without injections. The opinion adopted by the CHMP is an intermediary step on Rybelsus’s path to patient access.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag